非小细胞肺癌ERCC1基因和β-tubulin Ⅲ基因的研究进展

Progression of ERCC1 gene and β- tubulin Ⅲ gene in non- small cell lung cancer

非小细胞肺癌(normal cell lung cancer,NSCLC)的发病率和死亡率近年明显增高,在新诊断的患者中,有65%已不能行手术治疗,因此化学治疗(化疗)是治疗非小细胞肺癌的主要手段。但是由于耐药的存在,化疗疗效有效率有限,治疗的有效率仅为20%-40%。近年来随着肿瘤分子生物学的发展,已发现ERCC1、β-tubulinⅢ等基因的表达水平和化疗药物疗效及预后密切相关,并有可能成为预测疗效进行个体化治疗的重要指标。根据基因表达水平及药物敏感情况选择个体化的化疗方案是肿瘤学研究和临床肿瘤化疗的趋势。

Nowadays,lung cancer remains the leading cause of cancer- related death, as well as being characterized by great morbidity. In newly diagnosed patients, 65% had not underwent surgical operation. Treating patients with non - small call lung cancer（NSCLC） is a daunting task, but during recent years new options have emerged. Platinum - based doublets remain the cornerstone of chemotherapy in non - small cell lung cancer, though it achieves a re- sponse rate only in the range from 20% to 40%. Biomarkers such as ERCC1, β-tubulinⅢ are widely investigated and have shown good perspective. By tailoring treatment guided by biomarkers,it is now possible to improve outcome and maintain stable quality of life. In the future, biomarkers need optimization of methodology and prospective valida- tion before clinical implementation.